

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : A61K 39/12, 31/66, 39/385 A61K 37/16, A01N 37/18	A1	(11) International Publication Number: WO 91/16072 (43) International Publication Date: 31 October 1991 (31.10.91)
(21) International Application Number: PCT/US91/02599 (22) International Filing Date: 16 April 1991 (16.04.91) (30) Priority data: 510,154 16 April 1990 (16.04.90) US (71) Applicants: PRESIDENT AND FELLOWS OF HARVARD COLLEGE [US/US]; 17 Quincy Street, Cambridge, MA 02138 (US). INSTITUT SUISSE DE RECHERCHES EXPERIMENTALES SUR LE CANCER [CH/CH]; Chemin des Boveresses, CH-1066 Epalinges (CH). (72) Inventors: KRAEHENBUHL, Jean-Pierre ; Sous la Croix, CH-1812 Rivax (CH). AMERONGEN, Helen, M. ; 89 Rockview Street, #2, Jamaica Plain, MA 02130 (US). NEUTRA, Marian, R. ; 43 Prospect Street, Sherborn, MA 01770 (US).		(74) Agent: FREEMAN, John, W.; Fish & Richardson, 225 Franklin Street, Boston, MA 02110 (US). (81) Designated States: AT (European patent), AU, BE (European patent), BF (OAPI patent), BG, BJ (OAPI patent), BR, CA, CF (OAPI patent), CG (OAPI patent), CH (European patent), CM (OAPI patent), DE (European patent), DK (European patent), ES (European patent), FI, FR (European patent), GA (OAPI patent), GB (European patent), GR (European patent), HU, IT (European patent), JP, KP, KR, LU (European patent), ML (OAPI patent), MR (OAPI patent), NL (European patent), NO, RO, SE (European patent), SN (OAPI patent), SU, TD (OAPI patent), TG (OAPI patent). Published <i>With international search report.</i>
(54) Title: HYDROXYAPATITE-ANTIGEN CONJUGATES AND METHODS FOR GENERATING A POLY-IG IMMUNE RESPONSE (57) Abstract A method for generating antigen-sensitized Ig-A-producing lymphoblasts in a mammal, using an immunogen comprising an antigen or antigen mixture in association with hydroxylated calcium phosphate (hydroxyapatite) is administered to a mucosal surface of the mammal.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MG	Madagascar
AU	Australia	FI	Finland	ML	Mali
BB	Barbados	FR	France	MN	Mongolia
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Faso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GN	Guinea	NL	Netherlands
BJ	Benin	GR	Greece	NO	Norway
BR	Brazil	HU	Hungary	PL	Poland
CA	Canada	IT	Italy	RO	Romania
CF	Central African Republic	JP	Japan	SD	Sudan
CG	Congo	KP	Democratic People's Republic of Korea	SE	Sweden
CH	Switzerland	KR	Republic of Korea	SN	Senegal
CI	Côte d'Ivoire	LI	Liechtenstein	SU	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
CS	Czechoslovakia	LU	Luxembourg	TG	Togo
DE	Germany	MC	Monaco	US	United States of America
DK	Denmark				

-1-

HYDROXYAPATITE-ANTIGEN CONJUGATES
AND METHODS FOR GENERATING A
POLY-IG IMMUNE RESPONSE

5 Background of the Invention

This invention was made in part with funding from the United States Government, and the U.S. Government has certain rights in the invention.

10 This invention relates to the general fields of passive mucosal immune protection, and of poly-Ig immune reagents and techniques. We use the term poly-Ig to refer to the polymeric classes of antibodies--i.e. IgA and IgM. IgM antibodies are generally produced at an early stage of the immune response and are not an
15 important factor in protective mucosal immunity. Thus, the invention generally refers to polymeric Ig antibodies, and the usual and preferred antibodies for all aspects of the invention are IgA class antibodies, which normally are secreted in dimeric form and, to a
20 lesser degree, as higher IgA polymers.

 Many pathogenic bacteria and viruses initially gain entry into the body by crossing the cellular linings (epithelia) of the gastrointestinal, respiratory, or genital tracts. A specialized class of antibodies, IgA
25 antibodies, protects these surfaces. IgA antibodies are dimeric or polymeric molecules produced by cells located in the tissues under the epithelial surfaces. They are transported by epithelial cells into mucosal secretions, where they cross-link or coat pathogens that have not yet
30 entered the body, preventing the pathogens from contacting and adhering to epithelial cells. Thus, IgA antibodies operate on pathogens that are outside the body, and they protect by preventing entry into the body across epithelial surfaces.

- 2 -

The naturally occurring IgA response is triggered by antigen delivery to mucosal surfaces. The antigen enters the body through specific sampling sites (termed microfold or M cells) that effect transepithelial antigen transport to areas of the mucosal lining containing specialized, organized collections of the cells of the mucosal immune system. More specifically, as shown in Fig. 1, antigens A (shown as filled dots) in lumen 1 bind the luminal surface of M cells at site 2. The antigens are internalized and transcytosed at 3 to be released in the intra-epithelial pocket 4 containing lymphoid cells L (B and T cells) and antigen-processing/presenting cells such as macrophage cells (M).

IgA antibodies in a naturally immunized host are transported into secretions by binding to a specific receptor (called the poly-Ig receptor) on the basal (interior) surfaces of epithelial and glandular cells throughout the respiratory and digestive systems, the genital tract, and the mammary glands. See Solari and Kraehenbuhl, "Receptor-Mediated Transepithelial Transport of Polymeric Immunoglobulins", pp.269-298 in The Mammary Gland, Nelville and Daniel Eds., Plenum Publishing, Cambridge (1987); Mestecky (1987) J. Clin. Immunol. 7:265-276. Receptor-IgA complexes are transported across these cells and exocytosed onto luminal (exterior) cell surfaces where the receptor is enzymatically cleaved, releasing IgA into secretions along with a receptor fragment called secretory component (SC). See Mostov et al. (1980) Proc. Nat'l Acad. Sci. U.S.A. 77:7257-7261; Solari, R. and Kraehenbuhl, J.P. Cell 36:61-71 (1984); Kuhn and Kraehenbuhl, J. Biol. Chem. 256:12490-12495(1981). It is reported that secretory component reduces proteolytic degradation of IgA. Lindh, J., J. Immunol. 114:284-286 (1975); Brown, Neucomb, Ishizaka, J. Clin. Invest. 49:1374 (1974).

- 3 -

In general, existing immunization strategies which involve injection of antigens evoke production of the IgG class of antibodies that circulate systemically and neutralize pathogens after they have entered the body.

- 5 Injection of antigens does not generally evoke a substantial IgA response.

Efforts to take advantage of IgA protection at mucosal barriers involve oral immunization, either for active protection of the immunized mammal or for passive
10 protection of another mammal using mucosal secretion of the immunized mammal. Glass et al., New Eng. J. Med., 308:1389-1392 (1983); Fubara et al., J. Immunol., 111(2):395-403 (1973). Monoclonal IgA antibodies have been produced and applied directly to respiratory mucosal
15 surfaces in an effort to protect against pathogen entry. Mazanec et al. J. Virol., 61:2624-2625 (1987).

Active immunization may involve challenge at the mucosal surface with intact (killed) bacteria or viruses. To avoid dangers that may be associated with this
20 approach for certain pathogens, component antigens, such as immunogenic surface components of the pathogen, are applied at a mucosal surface. In some cases, the antigens have been conjugated to larger molecules. For example, the cholera toxin B subunit has been conjugated
25 to antigens. See, Czerkinsky et al. who report oral administration of a streptococcal antigen coupled to cholera toxin B subunit in Infection and Immunity 57:1072-1077 (1989). Biodegradable microspheres have also been used as an antigen carrier. For example,
30 Eldridge et al. Curr. Top. Microbial Immunol. 146:59 et seq. (1989) report incorporation of antigen into biodegradable microspheres. The dry protein antigen is dispersed in a copolymer matrix without chemical conjugation.

35

Summary of the Invention

- 4 -

We have discovered that hydroxylated calcium phosphate (HCP) particulate is a particularly useful carrier for therapeutics to be introduced through mucosal surfaces. Conjugates of HCP and therapeutically active ingredients (e.g., biologically active substances such as antigens, or drugs) are transported across epithelium where they produce the desired therapeutic response-- e.g. they raise a poly Ig immune response.

In its most general formulation, the invention features administering an active ingredient to a mammal by applying a complex of hydroxylated calcium phosphate and the active ingredient to a mucosal surface of the mammal.

One specific embodiment of the invention generally features a method for generating antigen-sensitized Ig-A-producing lymphoblasts in a mammal. In that method, an immunogen comprising an antigen or antigen mixture in association with hydroxylated calcium phosphate (HCP) particulate is administered to a mucosal surface of the mammal. In preferred embodiments of this first aspect of the invention, the antigen-sensitized lymphoblasts are recovered and immortalized to yield an Ig-A producing hybridoma.

A second specific embodiment of the invention features a method for vaccinating a mammal (especially a human) comprising administering the above-described immunogen to a mucosal surface of the mammal.

Alternative embodiments feature delivery of therapeutics (e.g., drugs) across the mucosa.

The invention also generally features a composition of matter comprising an active ingredient in association with hydroxylated calcium phosphate particles of a size suitable for transport across epithelium.

In any of the preferred embodiments of the invention, the hydroxylated calcium phosphate is in the

- 5 -

form of microparticles suitable for transport across the epithelium. Also preferably, the antigen comprises an externally available determinant of a pathogen or of spermatozoa, such as a viral coat or envelope protein, a lipopolysaccharide or a cell-surface protein. One form of HCP is hydroxyapatite (HA), a commercially available crystalline hydroxylated calcium phosphate discussed below.

The preferred modes of administrations of the active ingredient according to the invention are orally, vaginally, nasally, rectally, ocularly or to the middle ear. Oral administration can provide delivery to other G.I. mucosa including the intestinal mucosa.

The invention provides an efficient, polyvalent complex that can adhere to the mucosa and can be transported efficiently across the epithelial barrier for its biological effect, e.g. for presentation to the mucosal immune system. Adsorption of active ingredients, particularly proteins, to HCP is relatively simple, rapid and cheap, making the invention economically feasible. Moreover, HCP has a high general affinity for the antigens of interest, including proteins and other antigens, making the invention broadly applicable. HCP is generally non-toxic, as evidenced by the fact that HA is an integral component of bone, and the systemic immune system routinely encounters HA during normal bone resorption, a process that occurs constantly at a microscopic level in healthy individuals. Accordingly, pure HA presumably can be safely administered without a host immune response, and administration can be repeated as a vehicle for the same or different antigens, without an anti-vehicle immune response. Moreover HCP, particularly HA, is relatively inexpensive. HA can readily be reduced to a size suitable for transepithelial transport by M cells; and such a reduced size is suitable

- 6 -

for ingestion by macrophages and other cells of the reticuloendothelial system, so as to enhance immune response. Finally, M-cell uptake and transport of immunogens according to the invention is relatively
5 selective.

Other features and advantages of the invention will be apparent from the following description of the preferred embodiments thereof.

Description of the Preferred Embodiments

10 Figures

Fig. 1 is a diagrammatic representation of transcytosis of antigen across M cells.

Reagents

In general, the methods and materials described
15 below can be used as part of strategies for IgA protection which are disclosed in greater detail in a commonly owned patent application filed by Neutra, Kraehenbuhl, and Weltzin, simultaneously with this application, entitled SYNTHETIC POLY-Ig RECEPTOR,
20 RECEPTOR-ANTIBODY COMPLEXES, PRODUCTION AND USE THEREOF, which application is hereby incorporated by reference. In particular, immunogens and methods according to the invention can be used with stabilizer protein as described in the above-referenced application to create
25 poly Ig reagents for passive immunization.

The preferred embodiments of the invention feature hydroxyapatite-antigen conjugates and their use. Specifically, hydroxyapatite is a modified form of crystalline calcium phosphate, $\text{Ca}_{10}(\text{PO}_4)_6(\text{OH})_2$. It is
30 used as a protein fractioning reagent, due to its generalized protein-binding ability. Commercially available HA generally consists of slab-like crystals that are chemically and physically analogous to inorganic HA in normal bone tissue. As long as the starting
35 material is free of contaminants, ingestion of HA should

- 7 -

be relatively safe as evidenced by the existence of nutritional calcium/phosphorus supplements derived from ground bone, which are designed to be ingested.

Commercial high resolution HA (from Calbiochem) consists of crystals varying widely in size. As provided by manufacturers, HA crystals are likely to be too large, on the whole, to efficiently cross epithelial barriers. For example, crystals over 1 μm in length are unlikely to be taken up by M cells. Therefore, for use in the invention, commercial HA crystals are broken into small, relatively uniform crystalline fragments, e.g., by sonication.

The resulting sonicated crystals vary somewhat in size but their size generally does not exceed 1 μm . Preferably a substantial portion of the HA is present as fragments of about 0.01-0.1 μm . Fragmentation may be measured either by electron microscopy and light scattering, using standard techniques.

HA binds most proteins with high avidity and speed at low or physiologically safe concentrations. Binding is thought to depend on interaction of calcium sites with acidic and phosphate groups of proteins, and interaction of phosphates with basic protein groups. Higher molecular weight proteins will tend to be more tightly adsorbed to HA, but protein charge also plays a role. One gram of HA, for example, can bind about 30 mg of bovine serum albumin. Thus, HA can efficiently trap protein antigen from dilute solutions without addition of crosslinking chemicals, without harsh or denaturing conditions, and without wasting valuable pure antigen.

Use

HA-adsorbed antigens can be used in active vaccination of humans or other mammals. The invention is particularly useful to protect against Pseudomonas aeruginosa, Hemophilus influenzae, Vibrio cholerae,

- 8 -

Bordetella pertussis, Corynebacterium diphtheriae,
Escherichia coli, Salmonella typhi and typhimurium,
Clostridium perfringens and other enteric clostridia,
Shigella dysenteriae, Shigella flexnerii Neisseria
5 gonorrhoeae, Trichomonas, Entameba histolytica, Giardia
lamblia, Streptococcus, respiratory syncytial virus,
rotavirus, reovirus, Human Immunodeficiency Virus, Human
T-Cell Lymphotropic Virus, Types I and II, polio virus,
Rhinovirus, influenza virus, herpes viruses, human
10 papilloma virus; AIDS 2° pathogens such as Pneumocystis,
and yeast such as monilia. The invention is also useful
to protect against allergens that contact the respiratory
or digestive mucosal surfaces. It is also useful to
protect against pregnancy by cross-linking spermatozoa in
15 the vagina, and preventing their movement through the
cervix and uterus.

In each case, an appropriate known antigen-- e.g.
whole pathogen or specific externally presented antigens
such as the viral coat protein, or bacterial cell-surface
20 proteins, pilus protein, lipopolysaccharides, viral
capsid or envelope protein, protozoal plasma membrane
surface component, spermatozoal surface proteins, or
respiratory allergens--are used. Toxoids, e.g. CRM-197,
and inactivated diphtheria toxin reported by Uchida et
25 al. J. Biol. Chem. 248:3838-3844 (1973) may be used. The
antigen is used according to the above procedure to
generate hybridomas secreting the desired protective
antibodies. As just a few examples, WO88/08437 (hereby
incorporated by reference) discloses a tcPA pilus protein
30 suitable for forming anti-V. cholerae monoclonal poly-Ig
antibodies. U.S. Pat. 4,725,669 discloses the HIV
(HTLV-III) envelope glycoprotein suitable for forming
anti-HIV poly-Ig monoclonal antibodies. The following
patents and patent applications disclose preparation of
35 antigens for protection against Streptococcal infections,

- 9 -

particularly infection by Group B Streptococcus: U.S. Pat. 4,367,221; 4,367,222; 4,367,223; 4,356,263; 4,207,414 (RE 31,672); and WO 87/06267.

Other suitable antigens are disclosed in Bacterial
5 Vaccines and Local Immunity Proceedings of the Sclavo International Conf., Siena, Italy 17-19 November 1986. Specific reagents suitable for HIV antigens are disclosed in AIDS Research and Reference Reagent Program, National
10 Institute of Health, June 1989. For example, gp 120 is sold by MicroGeneSys, Inc. Spermatozoa cell-surface antigens such as LDH-C4 are also known. See, e.g. Shaha et al. and Talwar et al. Vaccine 7:97-100 (1989); and Shaha et al. Int. J. Androl. 11:479 (1988).

Of particular significance in the selection of
15 antigens for practice of the invention is that mucosal protection involves cross-linking to prevent entry into the body, and this mechanism does not require that the polymeric antibody kill or "neutralize" the pathogen. In contrast, systemic (IgG) protection involves binding
20 which, to be effective, generally must neutralize the pathogen. Thus, not every IgG antibody which binds to the pathogen is protective, as illustrated by the existence of monoclonal antibodies that specifically bind Vibrio cholerae, but do not neutralize it in the sense of
25 preventing it from colonizing, growing and manifesting clinical symptoms in its host. The universe of antigens and determinants available to raise protective IgA antibodies is thus significantly increased.

Specifically, the HA-adsorbed antigen is prepared
30 according to the method outlined above with appropriate modifications for production in bulk. The HA-adsorbed antigen or antigen mixture is compounded in a physiologically acceptable vehicle, and applied directly to or delivered to the mucosal surface tissue, e.g., to
35 oral, nasal, rectal and/or vaginal surfaces. The

- 10 -

preparation is administered in an aerosol, a suspension, a capsule and/or a suppository. Those skilled in the art will understand how to formulate such vehicles by known techniques.

5 Use

The invention is also particularly useful for manufacture of IgA-producing hybridomas. Such hybridomas are readily produced by challenging a mammal, e.g., by applying the above described composition to a mucosal
10 surface, and then recovering a lymphoid cell from Peyer's patch mucosa or other mucosa which are rich in lymphoid tissue and then fusing the lymphoid cell to a myeloma cell by known techniques. See, e.g., the above-referenced commonly owned, simultaneously filed,
15 U.S. patent application USSN 07/510,161.

The following examples are provided to illustrate, but not to limit the invention.

Example 1

2 gm HA (Calbiochem) suspended in 20 ml PBS is
20 sonicated with a probe sonicator for 30 minutes at room temperate, using the high setting (140, 80% duty cycle, of a Microson cell disrupter (Heat Systems Ultrasonics, Inc., Farmingdale, NY). Average crystal size is approximately 0.01 x 0.1 μ m after sonication, as measured
25 by electron microscopy. Adequate sonication can be monitored by spectrophotometric absorbance. For example, absorbance (read at 650 nm) of a 2 mg/ml suspension before sonication was 0.108 O.D. units and after reduction of crystal size (as above), O.D. increased to
30 2.060.

Example 2

HA crystals of this size, coated to saturation with proteins of various sizes ranging from 65 kD (albumin) to 450 kD (ferritin), when introduced into the
35 intestinal lumen of mice and rabbits, were selectively

- 11 -

bound and transported by M cells of Peyer's patch. This method effectively delivers proteins to cells of the mucosal immune system, in a particulate immunogenic form.

For oral immunization of a 25-gram mouse: a small amount (e.g., 30 μ g) of protein in 200 μ l PBS is mixed with an appropriate amount (e.g., 1 mg of HA for 30 μ g protein) of presonicated and washed HA. The mixture is agitated for 1 hr. at 4°C, and HA is then pelleted by spinning for 2 min. at 10,000 rpm in a microfuge. The pellet is resuspended by vortexing or sonicating in 200 μ l of water which may contain a buffer to neutralize gastric acid.

Other embodiments are within the following claims.

- 12 -

Claims

1 1. A method for administering an active
2 ingredient to a mammal comprising administering a complex
3 to a mucosal surface of the mammal, said complex
4 comprising said active ingredient in association with
5 hydroxylated calcium phosphate.

1 2. The method of claim 1 in which the
2 hydroxylated calcium phosphate is present in the form of
3 particles suitable for transport across epithelium.

1 3. The method of claim 1 in which the complex is
2 an immunogen comprising an antigen or antigen mixture in
3 association with hydroxylated calcium phosphate.

1 4. The method of claim 3 in which the
2 administration of the complex generates IgA-producing
3 lymphoblasts in the mammal which are sensitized to the
4 antigen.

1 5. The method of claim 3 in which the
2 administration of the immunogen vaccinates the mammal,
3 protecting it against mucosally introduced agents that
4 present the antigen.

1 6. The method of claims 3, 4 or 5 in which said
2 antigen comprises an externally available determinant of
3 a pathogen or of spermatozoa.

1 7. The method of claims 3, 4 or 5 in which said
2 antigen is a viral coat protein, a viral envelope
3 protein, a cell-surface lipopolysaccharide, or a
4 cell-surface protein.

- 13 -

1 8. The method of claims 3, 4 or 5 in which said
2 immunogen is administered orally, vaginally, nasally,
3 rectally, ocularly, or to the middle ear.

1 9. The method of claim 4 further comprising
2 isolating and immortalizing a plurality of lymphoblasts
3 from said mammal and identifying among said immortalized
4 lymphoblasts at least one immortalized lymphoblast that
5 secretes IgA that is capable of specifically binding to
6 said antigen.

1 10. A composition of matter comprising an active
2 ingredient in association with hydroxylated calcium
3 phosphate microparticles of a size suitable for transport
4 across epithelium in association with the active
5 ingredient.

1 11. The composition of claim 10 wherein said
2 complex is an immunogen for raising a mucosal immune
3 response in a mammal, and said active ingredient
4 comprises an antigenic determinant to which an immune
5 response is desired.

1 12. The immunogen of claim 11 wherein said
2 antigenic determinant is an externally available
3 determinant of a pathogen or of spermatozoa.

1 13. The immunogen of claim 12 wherein said
2 antigenic determinant is a determinant of viral coat
3 protein, a viral envelope protein, a cell-surface
4 lipopolysaccharide, or a cell-surface protein.




FIG. 1

INTERNATIONAL SEARCH REPORT

International Application No PCT/US91/02599

I. CLASSIFICATION OF SUBJECT MATTER (In some cases classification symbols apply to the prior art)

According to International Patent Classification (IPC) or to both National Classification and IPC
IPC (5): A61K 39/12, 31/66, 39/385, 37/16; A01N 37/18
US.C1: 424/603, 88, 89; 514/7, 2

II. FIELDS SEARCHED

Minimum Documentation Searched

Classification System

Classification Symbols

U.S. C1: 424/603, 88, 89; 514/7, 2.

Documentation Searched other than Minimum Documentation
to the Extent that such Documents are Included in the Fields Searched *

III. DOCUMENTS CONSIDERED TO BE RELEVANT *

Category *	Citation of Document, ** with indication, where appropriate, of the relevant passages **	Relevant to Claim No. **
A	EP. A, 0,175,286 (MCW-RES. found) 26 March 1986, see abstract.	1, 3, 4
A	JP. A. 63.196.281 (Sumitomo Elec. 15 August 1988, see abstract.	10-13
A	JP. A, 59,101,145 (Showa) 11 June 1984, see abstract.	1-13
Y	US. A, 4,722,840 (Valenzuela et al) 02 February 1988, see entire document.	1-13

* Special categories of cited documents: **

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claims or which is cited to establish the public date of prior art or other special reason (is specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the procedure or theory underlying the invention

"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step

"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, each combination being obvious to a person skilled in the art

"Z" document number of the same patent family

IV. CERTIFICATION

Date of the Actual Completion of the International Search

Date of Mailing of the International Search Report

13 June 1991

17 JUL 1991

International Searcher's Name

ISA/US

Lila Feisee

BEST AVAILABLE COPY